Harmony Gold Mining reports 61% operating profit surge but output decline and copper capex weigh on HMY stock
Can selective Bb inhibition give NovelMed Therapeutics an edge in the multibillion-dollar PNH drug market?
Read More 2 minute read Pharma Industry News Spark Therapeutics’ Luxturna gains EU approval as first gene therapy for inherited retinal disease In a significant breakthrough for treating inherited vision loss, Pennsylvania-based Spark Therapeutics has received European Commission (EC) approval… bypharmanewsdailyNovember 24, 2018
